Related Experiment Video
Updated: Aug 6, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
Published on: January 12, 2022
A 59-year-old woman with refractory uveitis
Lisa R Koenig1, Eli L Diamond2, Jasmine H Francis1
1Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Purpose:
To describe a novel use of melphalan delivered via ophthalmic artery chemosurgery (OAC) in the treatment of refractory histiocytosis, and to demonstrate a durable response at four years of follow-up.
Methods:
Case report.
Results:
We present a case of histiocytosis, specifically Rosai-Dorfman-Destombes disease (RDD), masquerading as refractory anterior uveitis and nodular scleritis. The patient was effectively treated with cobimetinib and melphalan via OAC. The ophthalmic manifestations remain resolved, and the visual acuity is 20/20 at four years of follow-up.
Conclusions:
The novel and durable use of OAC melphalan in the management of ophthalmic RDD is described herein.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview